【製薬準大手】がん領域の新薬「オプジーボ」の普及拡大で急成長。
日付 | 信用売残 (解説) | 信用買残 (解説) | 信用倍率 (解説) |
---|---|---|---|
2021/2/26 | 42,600 | 2,683,700 | 63.00 |
2021/2/19 | 40,100 | 2,399,400 | 59.84 |
2021/2/12 | 44,600 | 2,401,900 | 53.85 |
2021/2/5 | 47,300 | 2,400,600 | 50.75 |
2021/1/29 | 45,500 | 2,453,900 | 53.93 |
2021/1/22 | 63,400 | 2,054,800 | 32.41 |
2021/1/15 | 62,700 | 2,048,500 | 32.67 |
2021/1/8 | 63,400 | 2,031,000 | 32.03 |
2020/12/30 | 50,500 | 2,021,200 | 40.02 |
2020/12/25 | 106,900 | 1,882,200 | 17.61 |
2020/12/18 | 87,800 | 1,874,500 | 21.35 |
2020/12/11 | 84,900 | 1,853,500 | 21.83 |
2020/12/4 | 58,200 | 1,824,600 | 31.35 |
2020/11/27 | 92,400 | 1,813,900 | 19.63 |
2020/11/20 | 95,000 | 1,849,100 | 19.46 |
2020/11/13 | 129,000 | 1,850,600 | 14.35 |
2020/11/6 | 190,000 | 1,870,200 | 9.84 |
2020/10/30 | 96,300 | 1,976,300 | 20.52 |
2020/10/23 | 107,100 | 1,781,100 | 16.63 |
2020/10/16 | 128,700 | 1,755,300 | 13.64 |
2020/10/9 | 132,800 | 1,743,900 | 13.13 |
2020/10/2 | 139,500 | 1,742,900 | 12.49 |
2020/9/25 | 270,000 | 1,675,400 | 6.21 |
2020/9/18 | 214,100 | 1,667,300 | 7.79 |
2020/9/11 | 171,800 | 1,683,900 | 9.80 |
2020/9/4 | 206,500 | 1,737,700 | 8.42 |